Lanwei Medical (301060.SZ) announced first-quarter results, net profit of 1.071,700 yuan, a decrease of 95% year-on-year
Lanwei Medical (301060.SZ) released its report for the first quarter of 2024. The company achieved revenue during the reporting period...
Lanwei Medical (301060.SZ): A total cost of 15.3867 million yuan to buy back 1.1612,000 shares
Gelonghui, April 2, 丨 Lan Wei Medical (301060.SZ) announced that as of March 31, 2024, the company had repurchased a total of 1.1612 million shares through the Shenzhen Stock Exchange stock trading system, accounting for 0.29% of the company's current total share capital. The highest transaction price was 14.23 yuan/share, the minimum transaction price was 9.69 yuan/share, and the total transaction amount was RMB 15.3867 million (excluding transaction fees).
Further Upside For Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) Shares Could Introduce Price Risks After 43% Bounce
Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) shareholders would be excited to see that the share price has had a great month, posting a 43% gain and recovering from prior weakness. Un
Investors Will Want Shanghai Labway Clinical Laboratory's (SZSE:301060) Growth In ROCE To Persist
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly,
Lanwei Medical (301060.SZ): A total cost of 14.9986 million yuan to buy back 0.28% of the shares
Gelonghui, Feb. 2: Lanwei Medical (301060.SZ) announced that as of January 31, 2024, the company had repurchased 1,121,200 shares of the company's shares through centralized bidding transactions through the Shenzhen Stock Exchange stock trading system, accounting for 0.28% of the company's current total share capital. The highest transaction price was 14.23 yuan/share, the minimum transaction price was 12.75 yuan/share, and the total transaction amount was RMB 14,998,563.00.
Investors Give Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) Shares A 27% Hiding
Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. For any long-
Lanwei Medical (301060.SZ): Pre-loss of 110 million yuan to 165 million yuan in 2023
Gelonghui, January 30, 丨 Lanwei Medical (301060.SZ) announced the 2023 annual results forecast. The net profit loss attributable to shareholders of listed companies during the reporting period was RMB 110 million to RMB 165 million, with a profit of RMB 617.328 million for the same period last year; net profit loss after deducting non-recurring profit and loss of RMB 124 million - RMB 185 million, and profit of RMB 644.4795 million. Reasons for changes in performance: 1. During the reporting period, due to a decrease in testing demand, the medical diagnosis service business revenue declined significantly, causing the company's net profit to decline. 2. Partial inspection of business accounts receivable
Shanghai Labway Clinical Laboratory Co., Ltd's (SZSE:301060) Market Cap Dropped CN¥397m Last Week; Private Companies Bore the Brunt
Key Insights Significant control over Shanghai Labway Clinical Laboratory by private companies implies that the general public has more power to influence management and governance-related decisions
Lanwei Medical (301060.SZ): A total cost of 10.254,200 yuan to buy back 751,500 shares
Gelonghui, January 4, 丨 Lan Wei Medical (301060.SZ) announced that as of December 31, 2023, the company had repurchased 751,500 shares of the company's shares through centralized bidding transactions through the Shenzhen Stock Exchange stock trading system, accounting for 0.19% of the company's current total share capital. The highest transaction price was 14.23 yuan/share, the minimum transaction price was 12.78 yuan/share, and the total transaction amount was RMB 10.254,200 (excluding transaction fees).
Lanwei Medical (301060.SZ): Not involved in the development and sale of synthetic protein products
Gelonghui December 28 丨 An investor asked Lanwei Medical (301060.SZ) on the investor interactive platform, “Does your company have biotechnological reserves of synthetic proteins? Or is there any product development and sales in this area?” The company replied that the company is not involved in the development and sale of synthetic protein products for the time being.
Sun Linjie, director of Lan Wei Medical (301060.SZ), did not reduce his holdings at the end of the period
Lan Wei Medical (301060.SZ) announced that company director Sun Linjie did not reduce his holdings of the company's shares during the current holdings reduction plan period...
Lanwei Medicine (301060.SZ): Gene-edited drugs are currently not related to the company's testing business
On December 12, Gelonghui Medical (301060.SZ) stated on the investor interactive platform that gene-editing drugs are currently not related to the company's testing business, and whether expansion is necessary requires more extensive and in-depth research.
Lanwei Medicine (301060.SZ): The company has sufficient testing capabilities and technical reserves for mycoplasma pneumoniae and drug resistance genetic testing
On December 12, Gelonghui Medical (301060.SZ) stated on the investor interactive platform on December 12 that the company has sufficient testing capabilities and technical reserves for mycoplasma pneumoniae and drug resistance genetic testing to meet customer needs.
Lanwei Medical (30100.SZ): The initial repurchase of 65,000 shares involved 914,900 yuan
Gelonghui Medical (30100.SZ) announced on December 8, 2023/12, that as of December 8, 2023, the company has repurchased the company's shares through centralized bidding transactions for the first time through a special securities repurchase account. The number of shares repurchased this time is 65,000 shares, accounting for 0.0162% of the company's current total share capital. The maximum transaction price is 14.23 yuan/share, the minimum transaction price is 13.95 yuan/share, and the transaction amount is 9148.57 million yuan (excluding transaction fees).
Lanwei Medical (301060.SZ): No share repurchase has been implemented yet
Gelonghui on December 5 | Lanwei Medical (301060.SZ) announced that as of November 30, 2023, the company has opened a special repurchase securities account at the Shenzhen branch of China Securities Registration and Settlement Co., Ltd., and the company has not yet implemented a share repurchase.
Lanwei Medical (30100.SZ) plans to spend 15 million yuan to 30 million yuan to buy back the company's shares
Lanwei Medical (301060.SZ) issued an announcement that the company plans to use its own capital through the trading department of the Shenzhen Stock Exchange...
Lanwei Medical (30100.SZ) released the first three quarter results, with a net loss of 881,000 yuan
Lanwei Medical (301060.SZ) released its report for the third quarter of 2023, achieving revenue of 12 in the first three quarters...
Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
With its stock down 18% over the past three months, it is easy to disregard Shanghai Labway Clinical Laboratory (SZSE:301060). However, stock prices are usually driven by a company's financials over
[Instant Analysis of BT Financial Report] Lanwei Medical's 2023 Interim Report: Key Metrics such as Net Assets, Balance Ratio, and Gross Margin
Lanwei Medical (stock code: 301060) is a leading comprehensive service provider in the laboratory and diagnosis industry. It provides third-party medical testing and pathological diagnosis services, as well as in vitro diagnostic products and other professional technical support from well-known domestic and foreign brands. After years of development, the company has established a systematic, large-scale and networked service system. It is committed to becoming an effective complement to public medical institutions, providing comprehensive testing and diagnosis programs and specialized services for medical institutions. Now let's take a look at the financial data for Lanwei Medical's 2023 interim report. First, we see that the total closing balance of the company's assets is 32
Hailan Group, the majority shareholder of Lan Wei Medical (301060.SZ), reduced its holdings by a total of 3.622 million shares until the end of the holdings reduction period
Lan Wei Medical (301060.SZ) issued an announcement. The shareholder of the company holds more than 5% of the shares, Hailan Group Co., Ltd. (hereinafter...
No Data